We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
-4.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$44.1B
AUM Growth
+$629M
(+1.4%)
Cap. Flow
+$2.39B
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
11.51%
Holding
3,945
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halliburton
HAL
|
+$500M |
| 2 |
Archer Daniels Midland
ADM
|
+$463M |
| 3 |
Hewlett Packard
HPE
|
+$425M |
| 4 |
Gen Digital
GEN
|
+$379M |
| 5 |
WCC
WESCO International
WCC
|
+$269M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vistra
VST
|
+$598M |
| 2 |
ExxonMobil
XOM
|
+$504M |
| 3 |
Chevron
CVX
|
+$443M |
| 4 |
Occidental Petroleum
OXY
|
+$439M |
| 5 |
Cummins
CMI
|
+$414M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.1% |
| 2 | Technology | 16.69% |
| 3 | Energy | 13.9% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INFN
1326
DELISTED
Infinera Corporation Common Stock
INFN
| $18.1K | ﹤0.01% |
2,977
-664
| -18% | -$3.51K |
|
1327
ADMA Biologics
ADMA
$1.98B
| $17.8K | ﹤0.01% |
1,592
-1,582
| -50% | -$13.3K |
|
1328
PTC Therapeutics
PTCT
$6.34B
| $17.5K | ﹤0.01% |
571
-796
| -58% | -$25.8K |
|
1329
Vericel Corp
VCEL
$2.33B
| $17.3K | ﹤0.01% |
376
-429
| -53% | -$20.2K |
|
1330
Recursion Pharmaceuticals
RXRX
$1.63B
| $17K | ﹤0.01% |
2,263
-1,549
| -41% | -$13.5K |
|
1331
Rhythm Pharmaceuticals
RYTM
$7.36B
| $17K | ﹤0.01% |
413
-605
| -59% | -$24.1K |
|
1332
Apogee Therapeutics
APGE
$10.2B
| $16.8K | ﹤0.01% |
426
+116
| +37% | +$5.63K |
|
1333
NETSCOUT
NTCT
$2.85B
| $16.7K | ﹤0.01% |
914
-224
| -20% | -$4.42K |
|
1334
BioCryst Pharmaceuticals
BCRX
$2.49B
| $16.4K | ﹤0.01% |
2,649
-4,657
| -64% | -$25.7K |
|
1335
Nurix Therapeutics
NRIX
$2.43B
| $16.3K | ﹤0.01% |
781
-204
| -21% | -$3.18K |
|
|
AKRO
1336
DELISTED
Akero Therapeutics
AKRO
| $16.1K | ﹤0.01% |
688
-677
| -50% | -$14.5K |
|
1337
ImmunityBio
IBRX
$7.3B
| $15.7K | ﹤0.01% |
2,478
-3,619
| -59% | -$23.9K |
|
1338
Kymera Therapeutics
KYMR
$9.14B
| $15.4K | ﹤0.01% |
517
-464
| -47% | -$16.1K |
|
1339
Keros Therapeutics
KROS
$204M
| $14.9K | ﹤0.01% |
327
-233
| -42% | -$12.5K |
|
1340
Protagonist Therapeutics
PTGX
$8.77B
| $14.8K | ﹤0.01% |
428
-685
| -62% | -$20.1K |
|
1341
Kura Oncology
KURA
$928M
| $14.6K | ﹤0.01% |
709
-742
| -51% | -$15.3K |
|
|
SMAR
1342
DELISTED
Smartsheet Inc.
SMAR
| $14.5K | ﹤0.01% |
328
-711
| -68% | -$28.3K |
|
|
MORF
1343
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.4K | ﹤0.01% |
424
-606
| -59% | -$18K |
|
1344
Rocket Pharmaceuticals
RCKT
$361M
| $14.4K | ﹤0.01% |
669
-859
| -56% | -$19.7K |
|
1345
Arcutis Biotherapeutics
ARQT
$3.51B
| $13.7K | ﹤0.01% |
1,476
-2,399
| -62% | -$21.7K |
|
1346
Veracyte
VCYT
$4.47B
| $13.6K | ﹤0.01% |
626
-811
| -56% | -$17.1K |
|
1347
Mirum Pharmaceuticals
MIRM
$6.94B
| $13.4K | ﹤0.01% |
392
-848
| -68% | -$22.2K |
|
1348
Myriad Genetics
MYGN
$527M
| $13K | ﹤0.01% |
532
-628
| -54% | -$13.8K |
|
1349
Sportradar
SRAD
$4.35B
| $12.7K | ﹤0.01% |
1,138
-24
| -2% | -$250 |
|
|
SLNO
1350
DELISTED
Soleno Therapeutics
SLNO
| $12.5K | ﹤0.01% |
307
-184
| -37% | -$7.8K |
|
Similar funds
SAM
Pacer Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Pacer Advisors held 3,945 positions worth $44.1B, up 1.4% from $43.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $2.39B of net new capital in Q2 2024, opening 199 new positions and adding to 895 existing holdings. Its largest new stake was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Vistra, an estimated $598M trimmed.
- Pacer Advisors's largest Q2 2024 buy was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
- Pacer Advisors added most to Halliburton in Q2 2024, an estimated $500M increase.
- Pacer Advisors's biggest Q2 2024 reduction was Vistra, cutting an estimated $598M.
- Pacer Advisors fully exited American Eagle Outfitters in Q2 2024, selling an estimated $218M.
- Pacer Advisors's ten largest holdings make up 12% of its $44.1B portfolio in Q2 2024.
- Pacer Advisors opened 199 new positions and closed 190 in Q2 2024.
- Pacer Advisors's portfolio value rose 1.4% quarter-over-quarter to $44.1B.
Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.